Lexaria Bioscience Revenue vs. Return On Asset
| LEXXW Stock | USD 0.80 0.05 6.67% |
Total Revenue | First Reported 2007-05-31 | Previous Quarter 84 K | Current Value 84 K | Quarterly Volatility 109.6 K |
For Lexaria Bioscience profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lexaria Bioscience to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lexaria Bioscience Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lexaria Bioscience's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lexaria Bioscience Corp over time as well as its relative position and ranking within its peers.
Lexaria |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexaria Bioscience. If investors know Lexaria will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexaria Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.039 | Quarterly Revenue Growth 0.081 | Return On Assets (0.38) | Return On Equity (0.71) |
The market value of Lexaria Bioscience Corp is measured differently than its book value, which is the value of Lexaria that is recorded on the company's balance sheet. Investors also form their own opinion of Lexaria Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Lexaria Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexaria Bioscience's market value can be influenced by many factors that don't directly affect Lexaria Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexaria Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexaria Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexaria Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lexaria Bioscience Corp Return On Asset vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lexaria Bioscience's current stock value. Our valuation model uses many indicators to compare Lexaria Bioscience value to that of its competitors to determine the firm's financial worth. Lexaria Bioscience Corp is rated third overall in revenue category among its peers. It also is rated third overall in return on asset category among its peers . At this time, Lexaria Bioscience's Total Revenue is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lexaria Bioscience by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Lexaria Revenue vs. Competition
Lexaria Bioscience Corp is rated third overall in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 54.93 Million. Lexaria Bioscience maintains roughly 464,278 in revenue contributing less than 1% to equities under Health Care industry.
Lexaria Return On Asset vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Lexaria Bioscience |
| = | 464.28 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Lexaria Bioscience |
| = | -0.38 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Lexaria Return On Asset Comparison
Lexaria Bioscience is currently under evaluation in return on asset category among its peers.
Lexaria Bioscience Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lexaria Bioscience, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lexaria Bioscience will eventually generate negative long term returns. The profitability progress is the general direction of Lexaria Bioscience's change in net profit over the period of time. It can combine multiple indicators of Lexaria Bioscience, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -22.8 K | -23.9 K | |
| Operating Income | -5.8 M | -5.5 M | |
| Income Before Tax | -5.8 M | -5.5 M | |
| Total Other Income Expense Net | -42.2 K | -44.3 K | |
| Net Loss | -5.8 M | -5.5 M | |
| Income Tax Expense | 117.8 K | 123.7 K | |
| Net Loss | -3.5 M | -3.7 M | |
| Net Interest Income | 49.7 K | 52.2 K | |
| Net Loss | -6 M | -6.3 M | |
| Interest Income | 49.7 K | 52.2 K | |
| Net Loss | (0.47) | (0.07) | |
| Income Quality | 0.85 | (0.93) | |
| Net Income Per E B T | 1.00 | 1.16 |
Lexaria Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lexaria Bioscience. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lexaria Bioscience position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lexaria Bioscience's important profitability drivers and their relationship over time.
Use Lexaria Bioscience in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexaria Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexaria Bioscience will appreciate offsetting losses from the drop in the long position's value.Lexaria Bioscience Pair Trading
Lexaria Bioscience Corp Pair Trading Analysis
The ability to find closely correlated positions to Lexaria Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexaria Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexaria Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexaria Bioscience Corp to buy it.
The correlation of Lexaria Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexaria Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexaria Bioscience Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexaria Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lexaria Bioscience position
In addition to having Lexaria Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Size And Style ETFs Thematic Idea Now
Size And Style ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Size And Style ETFs theme has 1092 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Size And Style ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.